Assessing the best time interval between doses in a two-dose vaccination regimen to reduce the number of deaths in an ongoing epidemic of SARS-CoV-2

Leonardo Souto Ferreira, Otavio Canton, Rafael Lopes Paixão da Silva, Silas Poloni, Vítor Sudbrack, Marcelo Eduardo Borges, Caroline Franco, Flavia Maria Darcie Marquitti, José Cássio de Moraes, Maria Amélia de Sousa Mascena Veras, Roberto André Kraenkel, Renato Mendes Coutinho

1 Instituto de Física Teórica, Universidade Estadual Paulista, São Paulo, Brazil, 2 Observatório COVID-19 BR, São Paulo, Brazil, 3 Department of Ecology and Evolution, University of Lausanne, Lausanne, Switzerland, 4 Centro de Matemática, Computação e Cognição, Universidade Federal do ABC, Santo André, Brazil, 5 Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, 6 Instituto de Física 'Gleb Wataghin' and Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Brazil, 7 Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil

* leonardo.souto@unesp.br

Abstract

The SARS-CoV-2 pandemic is a major concern all over the world and, as vaccines became available at the end of 2020, optimal vaccination strategies were subjected to intense investigation. Considering their critical role in reducing disease burden, the increasing demand outpacing production, and that most currently approved vaccines follow a two-dose regimen, the cost-effectiveness of delaying the second dose to increment the coverage of the population receiving the first dose is often debated. Finding the best solution is complex due to the trade-off between vaccinating more people with lower level of protection and guaranteeing higher protection to a fewer number of individuals. Here we present a novel extended age-structured SEIR mathematical model that includes a two-dose vaccination schedule with a between-doses delay modelled through delay differential equations and linear optimization of vaccination rates. By maintaining the minimum stock of vaccines under a given production rate, we evaluate the dose interval that minimizes the number of deaths. We found that the best strategy depends on an interplay between the vaccine production rate and the relative efficacy of the first dose. In the scenario of low first-dose efficacy, it is always better to vaccinate the second dose as soon as possible, while for high first-dose efficacy, the best strategy of time window depends on the production rate and also on second-dose efficacy provided by each type of vaccine. We also found that the rate of spread of the infection does not affect significantly the thresholds of the best window, but is an important factor in the absolute number of total deaths. These conclusions point to the need to carefully take into account both vaccine characteristics and roll-out speed to optimize the outcome of vaccination strategies.
Science responded quickly to the COVID-19 pandemic, and many vaccines became available to contain the disease severity around the world. With a wide variety of vaccines, decision makers need to choose the best time interval between the doses of vaccines to apply in a population, given the epidemic situation and the efficacy of the different vaccines. In this work, we studied the best interval between doses of three different vaccines against COVID-19 using a mathematical model. For the modeling, we took into account individuals of different age groups, as they respond differently to vaccination depending on their age, and also the efficacy of vaccines after one dose and after complete vaccination (2 doses). We evaluated which interval between doses leads to fewer deaths. We found that if the efficacy of the first dose is low compared to complete vaccination, then vaccinating the second dose at a short interval leads to fewer deaths. On the other hand, if the efficacy of the first dose is high enough, the best strategy depends on vaccine availability. If vaccine supply is large, giving the second dose earlier is better. However, the postponement of the second dose results in fewer deaths in a situation of vaccine shortage.

Introduction

As the implementations of SARS-CoV-2 vaccination programs evolve in several countries around the world, governments must decide how to allocate doses among the population during the epidemic, usually prioritizing the most at-risk groups, such as healthcare workers, people with comorbidities, and older adults. In a context of limited vaccine supply, an optimized dose allocation strategy is critical to effectively immunize the population whilst achieving the best reduction in hospitalizations and deaths. On this basis, some countries considered partially protecting a greater percentage of the population by administering the first dose more widely at the expense of delaying second doses, and thus having less fully vaccinated individuals [1–3].

Vaccination programs can have different goals depending on the context and characteristics of both the disease and the available vaccines. The immunization program against Covid-19 has focused on reducing the burden of hospitalizations and deaths, which is justified given the risk of health care system collapse and the lack of vaccine supplies to quickly reach the high coverage required to substantially reduce infections. Another strong argument for that strategy is that many of the current vaccines are highly effective against hospitalization and death, but not in preventing new infections. For instance, AZD1222 (Oxford/AstraZeneca) has shown an efficacy of 86% (95% CI: 53–96%) against hospitalization [4], but 59.9% (95% CI: 35.8–75.0%) effective against new infections measured by nucleic acid amplification-positive tests [5]; for CoronaVac (Sinovac) this contrast is even starker with 83.7% (95% CI: 58.0–93.7%) efficacy against severe cases but only 50.7% (95% CI: 35.9–62.0%) for mild symptomatic cases as outcome [6]. Even BNT162b2 (Pfizer/BioNTech), which showed high efficacy against infections in the first trials [7] may provide a lower protection against new variants, as exemplified by the variant B.1.617.2 (also known as Delta) [8]. In this context, vaccination programs in many countries have prioritised the groups most at risk of developing severe disease, namely high exposure individuals (e.g. health care professionals), people with aggravating conditions, and older adults [9, 10].

Mathematical models in epidemiology have been widely used to assess optimal vaccination strategies for a variety of communicable diseases [11–15]. In a previous study on influenza
viruses, [16] explored how two different vaccination strategies (single dose or two dose) could be integrated into pandemic control plans of a limited vaccination supply. They conclude that the best strategy depends on the level of partial protection introduced by a single dose, but the study is limited to pre-pandemic vaccination scenario and does not capture vaccination roll-out during a pandemic.

Mass vaccination strategies have been proposed as the main approach to tackle the spread of SARS-CoV-2, complementing or replacing non-pharmaceutical interventions (NPIs). SIR-like models have pointed to the possibility of securely relaxing NPIs months after vaccination campaigns, depending on the rate of vaccination, as shown by [17]. The same work also suggests that, given a low roll-out rate scenario, one-dose strategies allow safe relaxation of NPIs sooner if the first dose corresponds to more than 80% of the vaccination protection (vaccination parameters based on BNT162b2). Although one-dose vaccination allows earlier relaxation of NPIs, it requires a slower transition to pre-pandemic levels for more vaccines to be delivered. The one-dose scheme is modelled as an effectively weaker vaccine, with no second doses being considered in the long run.

In this work we aim to find the best time-window between doses under different scenarios of relative efficacy of the first dose and infection rate in the population. We assess these scenarios for the three most used vaccine platforms, namely inactivated virus, viral vector of adenovirus, and mRNA-based vaccines. Given that most vaccination protocols require a second dose, we introduce a mathematical model that rigorously describes a two-dose vaccination scheme and optimal allocation of vaccines through delay differential equations. We explore the consequences of different strategies regarding the time-window between the two vaccine doses. The distribution of available vaccines for the first and second dose is optimized for each between-doses time interval, assuming a constant production rate. The partial protection offered by single-dose vaccination compared to double-dose vaccination is controlled by a single relative efficacy parameter. The best strategy, considering time interval between doses for the vaccine type, is defined based on the lowest total number of deaths in the range of time analysed. We find that the best strategy depends on the interplay between the vaccine production rate and the single-dose relative efficacy, with the effective reproduction number being an important factor for the reduction of deaths.

**Methods**

To investigate the impact on total hospitalizations and mortality of delaying the second dose in a two-dose vaccination roll-out during an ongoing epidemic, we built a model that takes into account the severity of the disease, age classes (the main risk factor for severity and death), and vaccination status.

Our model consists of an SEIR model extended to account for asymptomatic, severe/hospitalized, and deceased individuals, thus being named SEAIHRD, corresponding to susceptible, pre-symptomatic, asymptomatic, mildly symptomatic, severely symptomatic/hospitalized, recovered, and deceased classes respectively. Each epidemiological class comprises three age classes, namely children and teenagers (0–19), adults (20–59), and older adults (60+) classes. To account for vaccinated individuals with one or two doses, we have duplicated this set of classes for individuals who received one dose and two doses, which have different epidemiological parameters, as discussed below. The model structure is shown in Fig 1 and the model equations are presented in the supplementary information (S1 Text).

The demographic characteristics of the population were based on the State of São Paulo, Brazil. The basic epidemiological parameters come from current literature and are detailed in the S1 Text. The daily contact rates between age classes are based on the matrices projected by
[18], from which we use the Brazilian all-locations average for simplicity, reducing the age compartments using the same approach as in [19] (Supplementary material, section 3).

We assume a “leaky” vaccination effect, in which vaccinated individuals receives partial protection, in contrast to the “all-in” model where part of the vaccinated individuals receives full protection. [20] has shown that the outcome of these models do not differ substantially and the leaky model is simpler to understand and to implement.
The main parameters that describe the vaccination dynamics are the vaccine’s protective effect against (i) acquiring the disease, (ii) developing symptoms, (iii) developing severe symptoms (i.e., leading to hospitalization), and (iv) death. We present our analysis using sets of parameters that represent three types of vaccine developed for Sars-Cov-2; inactivated virus (CoronaVac, from Sinovac), adenovirus-based vaccine (AZD1222, from AstraZeneca-Oxford) and mRNA (BNT162b2, from Pfizer-BioNTech). The parameters for each vaccine are shown in Table 1.

As the required parameters may not be available in the studies for each vaccine, specially regarding the efficacy of a single dose, we simplify the problem by assuming that the efficacy for each outcome is proportional to the efficacy after the second dose by a fixed ratio, called relative efficacy of the first dose. This is a key parameter influencing the model outcome: if it is too small it is better to vaccinate the second dose sooner, but the opposite should be expected if the efficacy with one dose is as large as with two doses. Thus, we vary this parameter over all reasonable values (0–100%).

As the efficacy related to a specific outcome can be caused by a multiplicative effect of efficacy related to another outcome, (for example, lower number of deaths caused by a lower number of hospitalizations), we translate mathematically the observed efficacies that come from field studies to the parameters used in the mathematical model, as described in the S1 Text. The values of parameters used in the model are given in Table 1. Notice that this mathematical translation makes the protection against clinical symptoms age-dependent and also makes the protection against hospitalization for BNT162b2 negative. The latter case occurs because the efficacy against hospitalization is lower than the efficacy against infectious contact, but when the parameters of protection are multiplied as in the model’s equations (S1 Text) the value of efficacy is recovered.

Since we aim to study vaccination roll-out during an ongoing epidemic, we set the initial conditions for recovered and infectious populations using estimated values from hospitalization data. The procedure follows closely the one presented in [19], and is described in S1 Text. We use epidemiological and demographic data from the state of São Paulo, Brazil, although we do not expect the results to change substantially from one region to another.

We do not explicitly implement non-pharmaceutical interventions in our study, opting instead to model different scenarios by fixing the initial value of the effective reproduction number $R_e$. Thus, we computed $R_e$ using the method of Next Generation Matrix (for details, see S1 Text) and chose the value of probability of infection per contact ($\beta$) that yields the

Table 1. Parameters related to vaccine efficacy.

| Parameter                          | Description                                             | CoronaVac | AZD1222 | BNT162b2 |
|------------------------------------|---------------------------------------------------------|-----------|---------|----------|
| $E_{β,w}$                          | Observed efficacy against infectious contact given second dose | 0.00$^a$  | 0.599 [5] | 0.90 [21] |
| $E_{α,w}$                          | Observed efficacy against clinical symptoms given second dose | 0.50 [6]  | 0.813 [5] | 0.94 [21] |
| $E_{σ,w}$                          | Observed efficacy against hospitalization given second dose | 0.83 [6]  | 0.900$^b$ | 0.87 [21] |
| $E_{μ,w}$                          | Observed efficacy against death given second dose       | 0.95$^b$  | 0.950$^b$ | 0.98$^b$  |
| $\epsilon_{β,w}$                   | Protection against infectious contact with second dose   | 0.000      | 0.599    | 0.900    |
| $\epsilon_{α,w}$                   | Protection against clinical symptoms given second dose   | [0.499, 0.498, 0.494] | [0.533, 0.533, 0.537] | [0.402, 0.415, 0.494] |
| $\epsilon_{σ,w}$                   | Protection against hospitalization of infected individual given second dose | 0.830      | 0.750    | -0.300   |
| $\epsilon_{μ,w}$                   | Protection against death of hospitalized cases given second dose | 0.706      | 0.500    | 0.846    |

$^a$ Assumed. There is no data available yet.

$^b$ Assumed. The value reported had no statistical significance.

The observed efficacies are obtained from trials or effectiveness studies. The parameters of protection are calculated through the method explained in the S1 Text.

https://doi.org/10.1371/journal.pcbi.1009978.t001
desired value of $R_t$ at the beginning of the simulation. We vary this initial $R_t$ between 0.9 and 1.4, accounting for potentially more transmissible variants [19, 22] or increased contact rates due to less rigid non-pharmaceutical interventions.

The distribution of vaccines follows the priority of age groups: first older adults, then adults, and at last children and teenagers [23]. We assume that serological tests are not performed before vaccination, therefore vaccination does not depend on the individual’s previous serological status. Thus, susceptible and recovered individuals are vaccinated proportionally to the compartment’s population size. Severe and symptomatic individuals do not receive doses while infectious due to noticeable infection. We also exclude pre-symptomatic and asymptomatic from vaccination, since it would lead to unrealistic immediate benefits and there is a window between the date of vaccination and the start of protective effects. Recovered individuals are assumed to be completely immune and, since we fix our simulation interval at 300 days, we consider that the effects of waning immunity can be negligible. Likewise, we ignore aging dynamics, since it would be relevant only at much longer time scales.

Our model specifies that the time between first and second doses ($a$) is fixed for all individuals, which leads to a delay differential equation formulation. In contrast, constant rate models, where individuals receive the second dose at a fixed rate with an exponential distribution of times, would imply that some of them immediately receive the second dose and lead to incorrect average times between doses when vaccination rates fluctuate over time. We also allow for a proportion $\theta$ of individuals that take the first but not the second dose, representing abandonment; this value is fixed at 0.1 throughout our simulations (in the case of CoronaVac vaccine phase 3 trial, the rate of abandonment was 0.16 [24]).

To optimally allocate the vaccination, keeping the number of stocked vaccines as low as possible while ensuring that second doses are available, we solve a delayed optimization problem that is described in the following section. After minimizing the vaccine stock for the different time interval between doses, we calculate the number of deaths each vaccine type and time interval produces, and we choose the time window for each vaccine by considering the one with the lowest number of deaths, and this is considered the best window.

### Optimizing vaccination roll-out

We write a dynamical equation for the vaccine stock $V(t)$ assuming a constant production (or deployment) rate $p$ and a varying withdrawal rate is given by the vaccination rate $v(t)$, which can be chosen, that is, it is the control variable. We impose that a constant fraction $\theta' = 1 - \theta$ of the people who take the first dose will receive the second one after a period $a$, so we must be careful that the total vaccination rate is the sum of both first and second dose vaccination rates and it is limited to a maximum rate of vaccination $v_{max}$, but the control variable is the vaccination rate of first doses only. We also assume that there’s an initial stock of vaccines $V_0$. The equation for $V(t)$ then is:

$$
\begin{aligned}
\frac{dV}{dt} &= p - v(t) - \theta'v(t-a) \\
V(0) &= V_0, \quad v(t) = 0 \forall t < 0
\end{aligned}
$$

We note already that we can solve this equation, obtaining

$$
V(t) = V_0 + pt - \int_0^t v(t')dt' - \theta' \int_0^{t-a} v(t')dt'
$$

We define the optimization problem by stating the objective function to be minimized and the restrictions that the solution must obey. Since we want to use vaccine doses as quickly as
possible, a reasonable goal is to minimize the stock of vaccines \( V(t) \). With that, we impose that the total vaccination rate is limited by a certain maximum value, and of course, it is positive; also, the vaccine stock \( V(t) \) is always positive. Finally, we must ensure that in the period after the simulation ends \(( t > T )\) there will be enough doses left to use as second doses on those who have already taken the first dose.

These considerations lead to the following optimization problem:

\[
\min \quad J = \int_0^T V(t) \, dt \\
\text{subject to} \quad v(t) \geq 0 \\
\quad v(t) + \theta' v(t - a) \leq v_{\text{max}} \\
\quad V(t) \geq 0 \\
\quad V(T) \geq \theta' \int_{T-a}^T v(t') \, dt' - pa
\]

**Solution.** We can solve the problem defined by Eqs (2) and (3) using linear programming. This is feasible because the objective function and all constraints are linear functions of the control variable \( v \) and state variable \( V \) and, as Eq (2) shows, \( V \) is linear on the control variable.

We first discretize the time in \( n \) intervals of length \( \Delta t = \frac{T}{n} \) each interval ending at \( t_i \), \( i = 1, \ldots, n \), and assume that the control function will be constant over each interval (that is, a step function), with values \( \bar{x} = (v(t_1), v(t_2), \ldots, v(t_n)) \). Eq (2) then becomes

\[
V(t_i) = V_0 + pt_i - \sum_{j=1}^{i} x_j - \theta' \sum_{j=1}^{i-a} x_j,
\]

and we seek to minimize the objective function (given by Eq (3), up to a constant) that is a linear function of \( \bar{x} \), subject to the (linear) restrictions.

The discrete version of the problem becomes:

\[
\min \quad J = \min \left[ -\sum_{j=1}^{n} \left[ \sum_{i=1}^{j} x_i + \theta' \sum_{i=1}^{j-a} x_i \right] \right] \\
\text{subject to} \quad \bar{x} \geq 0 \\
\quad x_i + \theta' x_{i-a} \leq v_{\text{max}}, \text{ for } i = 1, \ldots, n \\
\quad \sum_{i=1}^{j} x_i + \theta' \sum_{i=1}^{j-a} x_i \leq V_0 + pt_i, \text{ for } j = 1, \ldots, n \\
\quad (1 + \theta') \sum_{i=1}^{n} x_i \leq V_0 + p(t_n + a),
\]

where \( a = \frac{T}{n} \) (chosen so that \( a \) is integer), and, to simplify notation, \( x_i \) is taken to be zero over values of \( i \) below 1.

These conditions can readily be written in matrix form and solved using standard linear programming algorithms. We implemented them in R using the package lpSolve [25] to solve the linear programming problem.

Finally, to assess which conditions is best to employ a longer (up to 12 weeks) or shorter (at least 3 weeks) interval between first and second doses, we simulate the model and compute the
total number of deaths across all ages and vaccination status at the end of a period of 300 days, choosing as the best strategy of window the one that has the lowest number of deaths. We performed this comparison by varying the relative efficacy of the first dose and also the parameters related to the current rate of infection ($R_t$) and vaccine production rate.

**Results**

The optimal vaccine roll-out with time between doses of 3 and 12 weeks is shown in Fig 2. We can see that for reasonable parameters of production and vaccination rate for São Paulo State, the vaccine stock can be kept close to zero (i.e. all doses can be used immediately) after about 30 days after the beginning of vaccination when using a time interval of 3 weeks. For the time interval of 12 weeks, the stock is kept close to zero during the first stage of the first dose vaccination, but doses need to be stored to be used as second-doses for a small time window. In both cases, we see a pattern of alternating stages of first and second dose vaccination, while optimally keeping the stock of vaccines close to zero.

By varying the initial values of $R_t$ for a fixed production rate (Fig 3), we see that longer periods between the first and second doses led to a lower number of deaths when the relative efficacy of the first dose alone is higher than approximately 60%, whereas smaller time intervals are better if the relative efficacy is lower than approximately 50%, and intermediary periods are the best interval between doses if the relative efficacy is between 50% and 60%. It is also important to note that the value of initial $R_t$ does not substantially affect the value of relative efficacy where transitions between best time windows occur, but is an important factor in the absolute value of deaths.

Since our results show that the best time window is not strongly dependant on the value of $R_t$, we fixed this value at 1.1 and varied the relative efficacy and production rate. Then, we compare the best window relative to the reduction in deaths for several time window intervals.

![Fig 2. Vaccination rate as a function of time for first (solid, black) and second doses (dashed, grey)—Scale is given by the left y-axis. Number of stored vaccine doses as function of time (dot-dashed, blue), scale in the right y-axis. Taking into account 3 or 12 weeks (panels) as separation between doses. $V_0 = 2.83\%$ of population in doses, $\rho(t) = 0.23\%$ of population in doses/day, $v_{max} = 0.45\%$ of population in doses/day.](https://doi.org/10.1371/journal.pcbi.1009978.g002)
The result is computed by simulating a coarse grid of values and then linearly interpolating a finer mesh. For all vaccines, relative efficacy of the first dose below approximately 45% indicates that regardless of the vaccine production rate, the best strategy to reduce mortality is to complete the two-dose scheme 3 weeks after the initial dose. If the production rate is low (Fig 4). The reduction in total number of deaths as function of the first dose relative efficacy, considering three time windows between doses: 3, 7 and 12 weeks (colors); varying vaccine type (columns); and effective reproduction number at the start of simulation (rows). \( V_0 = 2.83\% \) of population in doses, \( \rho(t) = 0.23\% \) of population in doses/day, \( \nu_{\text{max}} = 0.45\% \) of population in doses/day.

https://doi.org/10.1371/journal.pcbi.1009978.g003
increasing the relative efficacy above 45% rapidly shifts the best time window to increasingly larger periods, and converges to the maximum interval of 12 weeks. However, on this same range for the relative efficacy of the first dose, increasing the production rates results in a non-linear transition to shorter time-windows.

Although it is expected that the best time window should always increase with higher relative efficacy, and decrease with higher production rate, the latter hypothesis is sometimes violated in the simulations (Fig 4). Despite that, the general pattern is largely unaltered.

**Discussion**

Our model evaluates the best time windows between first and second doses for individuals in a context of limited vaccine supply in the ongoing COVID-19 pandemic. We found that the time window that best reduces the mortality depends on the interplay between two key parameters: vaccine production rate and the relative efficacy of the first dose. Within the simulated regimes with low single-dose efficacy, the resulting best strategy consistently relied on allocating the available doses to complete the two-dose scheme at the shortest time possible to provide the vaccine’s maximum protection and minimize the mortality of the population.

However, when the first dose presents a higher level of relative efficacy and vaccine supply is restricted, the best strategy relied on prioritizing the allocation of doses to increase the proportion of the population receiving the first dose, resulting in a longer interval between doses to effectively allocate the use of the limited vaccine supply. Further, this interval is shortened by increasing the vaccine supply, as it progressively alleviates the conflict on dose allocation. Given that the effective reproduction number has little effect when considering the best window between doses, this further ensures the applicability of our results to other locations.

Another important parameter that varies across vaccines is the protection against infection, *i.e.* reduction in susceptibility, after the second dose, with values of 0, 0.6 and 0.9 for CoronaVac, AZD1222 and BNT162b2 respectively (See Table 1). This difference allows for larger delays with lower relative efficacy of the first dose, even with similar protection against deaths (0.95, 0.95, 0.98, in the same order) simply by avoiding new infections.
Given the key role of the efficacy of the first dose in deciding the best strategy to reduce mortality, it is worth considering the best available knowledge for the vaccines evaluated in this study. Preliminary results of the effectiveness of the inactivated virus vaccine CoronaVac in Chile have shown that the first-dose efficacy of that vaccine is substantially lower before the second dose vaccination, with effectiveness against symptomatic infection being 17.2% (95% CI: 15.8–18.6%) [26]. This result, together with previous studies concerning inactivated virus vaccines showing that the protection against infectious contact is likely to be low [27, 28], suggests that the safest strategy concerning second dose of CoronaVac is a three-week interval, the shortest recommended, to achieve the largest reduction in the number of deaths.

In the case of the adenovirus-based AZD1222 vaccine, [5] estimated 76.7% (95% CI: 47.0–89.8%) for the efficacy against symptoms 21 days after the first dose. Albeit this estimate provides reasonably high values, the small number of events results in great uncertainty on this estimate, reflected in its wide confidence intervals. [29] corroborates those results with effectiveness against having a positive RT-PCR test of 64% after 21 days (95% CI: 59–68%) in a study in the UK, but without differentiating between AZD1222 and BNT162b2. Using this value as a proxy of first dose efficacy compared to the efficacy against symptoms post second-dose, the relative efficacy would be around 80%, which, according to our results, would suggest that delaying the second dose can be an effective strategy, especially in lower production rates. The efficacy post second-dose using a window less than 6 weeks is substantially lower (55.1%, 95% CI: 33.0–69.9%) when compared to 12 weeks (81.3%, 95% CI: 60.3–91.2%) [5], providing another argument in support of delaying the second dose of AZD1222.

For the mRNA vaccine BNT162b2, [29] have shown that its effectiveness is very high 21 days after the first dose (78%, 95% CI: 72–83%), results corroborated by a study conducted by the [1], from the UK. With these values, together with very high post second-dose efficacy against infectious contacts, our model results entail that postponing the second dose is the best strategy. However, as this is the first known vaccine using the mRNA platform, it would be advisable to postpone the second dose only after studies assuring the efficacy of such vaccine in these conditions, as pointed out by [30].

Vaccines developed to have more than one dose usually benefit from increased interval between doses, presenting stronger immunogenic response with larger intervals [31]. Thus, by using the same efficacy of the second dose for any interval between doses, our results might have been biased, favoring shorter time intervals as the best strategies. Therefore, a more complete evaluation of best strategy would require efficacy information for any of the intervals studied. Due to the emergency situation vaccines were tested in their trials, few experiments were designed to analyse different time interval between doses (yet, check some data available in [5] for AZD1222 and [6] for CoronaVac). Future works can re-evaluate the choice of the best interval between doses when these data become available, especially if the immunogenic response and efficacy increases non-linearly with time interval.

Previous studies that have evaluated the best strategies for vaccination for COVID-19 have focused on the interplay between vaccination and non-pharmaceutical interventions [20, 32, 33]. More recently, some agent-based models estimated the reduction in deaths and infections if postponing the second dose: [34] found that delaying the second dose for BNT162b2 and mRNA-1273 (from Moderna) is usually the best strategy until it reaches peak values for longer intervals; [35] found that the results are even better in the scenarios of low vaccine production rates. We confirm these initial results and extend the analysis to more combinations of first dose efficacy and production rates, and also consider more types of vaccine. Our model also accounts for optimal allocation of vaccination rates of first and second doses, an issue not addressed in those works.
Using a differential equations formulation, [36] compared the strategies of “hold back” (storing half of the vaccines to guarantee the second dose) and “release” (vaccinating as much as first doses possible, while minimizing the backlog of second dose vaccination) and found that first dose efficacy is essential when deciding for the best vaccine protection coverage if delaying the second dose. Their results agree with ours but it has the limitation of not guaranteeing that the mean period with single-dose protection is preserved in a varying vaccination rate, which is only possible using a more complex formulation, such as delay differential equations as used here. They also argue that, while the “release” strategy enables better allocation of vaccines, in a real-world situation the implementation of such strategy is too complicated to manage. While we agree that this strategy adds a complication factor, we also believe that stock optimization models such as the one developed in this study could be linked to vaccination databases and, as the vaccination roll-outs to tackle the SARS-CoV-2 pandemic were centralized by the national health systems, thus allowing more efficient allocation of vaccines.

Throughout this study, we assumed that post second-dose efficacies do not depend on the time-window between doses, although evidence suggests that this is not the case for AZD1222 vaccine [5]. This simplifying assumption probably leads to a slight underestimation of the benefits of increasing the lag between doses for this vaccine. We have also assumed that first dose efficacy is constant over time, when in reality it builds up over approximately 2 weeks and wanes later on [29, 37]. This can be addressed using agent-based models [34], or age-of-infection models in a differential equations formulation, but that would greatly increase the complexity of the algorithm. This difficulty is also present when trying to compare model parameters to first dose efficacy in observational studies, as only the period after 14 days is usually considered, leaving a very short period in which events can occur. The impact of this on our conclusions can go in either direction: for shorter time windows, the efficacy in the model should be lower than the observed one, since for most of the time—the first 14 days—protection is virtually non-existent; while for longer time windows the same happens, that is, model parameters should be below measured efficacies due to waning effects of the vaccine. We currently do not have enough details of the profile of the immunological response over time to settle the issue definitively, yet we expect the pattern of the results to hold, given that we cover every possibility of relative efficacy and thus this can be compared to averaged values in time of the efficacy of the first dose.

In summary, we developed a novel approach to assess the best conditions to delay the second dose of three different vaccine platforms for COVID-19. Our approach consisted of using a SEIR-like model coupled with a delay differential equation vaccination model and optimization of vaccine stock. We found that the first dose efficacy relative to post second dose efficacy is an essential parameter when defining the best window between doses, but the vaccine production rate in each country can be also decisive. Finally, we also found that those results have little dependence on the current epidemic situation at the start of the simulation. Further research in this theme would include non-constant production rate in the optimization scheme, together with starting such model in an ongoing vaccination roll-out, as well as considering lower efficacy in different age bins and other dose prioritization schemes.

Supporting information

S1 Text. Model description. The accompanying file contains the mathematical description of the model, together with the epidemiological parameters used in the simulations. (PDF)
Acknowledgments

We are grateful for the collaborative work of the entire group of the Observatório COVID-19 BR. In particular, we thank Monica de Bolle, Verônica Coelho and Márcia Castro for critical inputs.

Author Contributions

Conceptualization: Leonardo Souto Ferreira, Otavio Canton, Rafael Lopes Paixão da Silva, Silas Poloni, Vítor Sudbrack, Marcelo Eduardo Borges, Caroline Franco, Maria Amélia de Sousa Mascena Veras, Roberto André Kraenkel, Renato Mendes Coutinho.

Data curation: Marcelo Eduardo Borges, Flavia Maria Darcie Marquitti, Maria Amélia de Sousa Mascena Veras.

Formal analysis: Leonardo Souto Ferreira, Otavio Canton, Silas Poloni, Renato Mendes Coutinho.

Investigation: Leonardo Souto Ferreira.

Methodology: Leonardo Souto Ferreira, Otavio Canton, Rafael Lopes Paixão da Silva, Silas Poloni, Vítor Sudbrack, Marcelo Eduardo Borges, Roberto André Kraenkel, Renato Mendes Coutinho.

Software: Leonardo Souto Ferreira, Otavio Canton, Rafael Lopes Paixão da Silva, Silas Poloni, Vítor Sudbrack, Marcelo Eduardo Borges, Caroline Franco, Renato Mendes Coutinho.

Supervision: Maria Amélia de Sousa Mascena Veras, Roberto André Kraenkel, Renato Mendes Coutinho.

Validation: José Cássio de Moraes.

Visualization: Leonardo Souto Ferreira, Flavia Maria Darcie Marquitti.

Writing – original draft: Leonardo Souto Ferreira, Silas Poloni, Vítor Sudbrack, Marcelo Eduardo Borges, Caroline Franco, Renato Mendes Coutinho.

Writing – review & editing: Flavia Maria Darcie Marquitti, José Cássio de Moraes, Maria Amélia de Sousa Mascena Veras, Roberto André Kraenkel.

References

1. JCVI. Optimising the COVID-19 vaccination programme for maximum short-term impact; 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact [Accessed: 2021-06-18].

2. MS. Décimo Quinto Informe Técnico—Orientações Técnicas Relativas à Continuidade da Campanha Nacional de Vacinação Contra a COVID-19; 2021. https://www.gov.br/saude/pt-br/media/pdf/2021/maio/3/anexo-decimo-quinto-informe-tecnico.pdf [Accessed: 2021-07-23].

3. PHE. COVID-19 vaccination programme—Information for healthcare practitioners; 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/999527/COVID-19_vaccination_programme_guidance_for_healthcare_workers_6July2021_v3.9.pdf [Accessed: 2021-07-23].

4. Stowe J, Andrews N, Gower C, Gallagher E, Utsi L, Simmons R, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant; 2021. https://media.tgfn.org/articles/Effectiveness_of_COVID-19_vaccines_against_hospital_admission_with_the_Delta_B.1.617.2.pdf [Accessed: 2021-07-26].

5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1
nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet. 2021; 397(10277):881–891. https://doi.org/10.1016/S0140-6736(21)00432-3 PMID: 33617777

6. Palacios R, Batista AP, Albuquerque CSN, Patiño EG, do Prado Santos J, Conde MTRP, et al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN Journal Electronic Journal. 2021; https://doi.org/10.2139/ssrn.3822780

7. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020; 383(27):2603–2615. https://doi.org/10.1056/NEJMoaa2034577 PMID: 33301246

8. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine. 2021; 385(7):585–594. https://doi.org/10.1056/NEJMoaa2108891

9. RKI. Epidemiologisches Bulletin 2/2021; 2021. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.html [Accessed: 2021-07-26].

10. MS. Plano Nacional de Operacionalização da Vacinação contra Covid-19; 2021. https://www.gov.br/saude/pt-br/coronavirus/publicacoes-tecnicas/guias-e-planos/plano-nacional-de-vacinacao-covid-19/view [Accessed: 2021-07-26].

11. Arino J, Brauer F, van den Driessche P, Watmough J, Wu J. A model for influenza with vaccination and antiviral treatment. Journal of Theoretical Biology. 2008; 253(1):118–130. https://doi.org/10.1016/j.jtbi.2008.02.026 PMID: 18402981

12. Ehrhardt M, Gašper J, Kilianová S. SIR-based mathematical modeling of infectious diseases with vaccination and waning immunity. Journal of Computational Science. 2019; 37:101027. https://doi.org/10.1016/j.jocs.2019.101027

13. Elbasha EH, Galvani AP. Vaccination against multiple HPV types. Mathematical Biosciences. 2005; 197(1):89–117. https://doi.org/10.1016/j.mbs.2005.05.004 PMID: 16095627

14. Greenhalgh D. Vaccination campaigns for common childhood diseases. Mathematical Biosciences. 1990; 100(2):201–240. https://doi.org/10.1016/0025-5564(90)90040-6 PMID: 2134473

15. Zhao S, Xu Z, Lu Y. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China. International Journal of Epidemiology. 2000; 29(4):744–752. https://doi.org/10.1093/ije/29.4.744 PMID: 10922354

16. Matrajt L, Britton T, Halloran ME, Longini IM Jr. One versus two doses: What is the best use of vaccine in an influenza pandemic? Epidemics. 2015; 13:17–27. https://doi.org/10.1016/j.epidem.2015.06.001 PMID: 26616038

17. Kraay ANM, Gallagher ME, Ge Y, Han P, Baker JM, Koelle K, et al. Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions. MedRxiv. 2021; https://doi.org/10.1101/2021.03.12.21253481

18. Prem K, van Zandvoort K, Klepac P, Eggo RM, Davies NG, Cook AR, et al. Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. PLOS Computational Biology. 2021; 17(7):e1009098. https://doi.org/10.1371/journal.pcbi.1009098 PMID: 34310590

19. Coutinho RM, Marquitti FMD, Ferreira LS, Borges ME, da Silva RLP, Canton O, et al. Model-based estimation of transmissibility and reinforcement of SARS-CoV-2 P.1 variant. Communications Medicine. 2021; 20(1). https://doi.org/10.1038/s43856-021-00048-6

20. Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021; 371(6532):916–921. https://doi.org/10.1126/science.abe6959 PMID: 33479118

21. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 2021; 384(15):1412–1423. https://doi.org/10.1056/NEJMoaa2101765

22. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538):eabg3055. https://doi.org/10.1126/science.abg3055 PMID: 33658326

23. SVS. Plano Nacional de Operacionalização da Vacinação contra a COVID-19; 2021. https://www.gov.br/saude/pt-br/media/pdf/2021/marco/23/plano-nacional-de-vacinacao-covid-19-de-2021 [Accessed: 2021-06-03].

24. ANVISA. Avaliação do Uso Emergencial da Vacina CoronaVac—Apresentação; 2021. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/confera-materiais-da-reuniao-extraordinaria-da-dicio/1-apresentacao-ggmed-coronavac.pdf [Accessed: 2021-07-21].

25. Berkelaar M, Eikland K, Notebaert P. IpSolve: Interface to ‘lp_solve’ v. 5.5 to Solve Linear/Integer Programs; 2020. R package version 5.6.15. Available from: https://CRAN.R-project.org/package=IpSolve.
26. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal of Medicine. 2021; 385(10):875–884. https://doi.org/10.1056/NEJ莫a2107715 PMID: 34233097

27. Afrough B, Dowall S, Hewson R. Emerging viruses and current strategies for vaccine intervention. Clinical & Experimental Immunology. 2019; 196(2):157–166. https://doi.org/10.1111/cei.13295 PMID: 30993690

28. Roper RL, Rehm KE. SARS vaccines: where are we? Expert Review of Vaccines. 2009; 8(7):887–898. https://doi.org/10.1586/erv.09.43 PMID: 19538115

29. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gettings O, Vihta KD, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature Medicine. 2021; 27(8):1370–1378. https://doi.org/10.1038/s41591-021-01410-w PMID: 34108716

30. Robertson JFR, Sewell HF, Stewart M. Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture? The Lancet. 2021; 397(10277):879–880. https://doi.org/10.1016/S0140-6736(21)00455-4 PMID: 33617766

31. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021; 184(23):5699–5714.e11. https://doi.org/10.1016/j.cell.2021.10.011 PMID: 34735795

32. Jentsch PC, Anand M, Bauch CT. Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study. The Lancet Infectious Diseases. 2021; https://doi.org/10.1016/S1473-3099(21)00057-8 PMID: 33811817

33. Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. The Lancet Infectious Diseases. 2021; 21(6):793–802. https://doi.org/10.1016/S1473-3099(21)00143-2 PMID: 33743847

34. Moghadas SM, Vilches TN, Zhang K, Nourbakhsh S, Sah P, Fitzpatrick MC, et al. Evaluation of COVID-19 vaccine strategies with a delayed second dose. PLOS Biology. 2021; 19(4):e3001211. https://doi.org/10.1371/journal.pbio.3001211 PMID: 33882066

35. Romero-Bruafu S, Chopra A, Ryu AJ, Gel E, Raskar R, Kremers W, et al. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ. 2021; p. n1087. https://doi.org/10.1136/bmj.n1087 PMID: 33980718

36. Mak HY, Dai T, Tang CS. Managing Two-Dose COVID-19 Vaccine Rollouts with Limited Supply. SSRN Electronic Journal. 2021; https://doi.org/10.2139/ssrn.3790836

37. Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. The Lancet Infectious Diseases. 2021; 21(11):1529–1538. https://doi.org/10.1016/S1473-3099(21)00289-9 PMID: 34174193